Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_82
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley